Medical journals and the FDA have announced birth control pills which combine the estrogen “ethinyl estradiol” with the progestin “drospirenone” lack adequate warnings about blood clots.
Studies published in the British Medical Journal found that women taking birth control pills containing drospirenone as their progestin compound were at more than 600% greater risk of suffering blood clots in comparison with women who took no oral contraceptive. Blood clots in the lungs, known as pulmonary embolism, can potentially kill a person. Blood clots in major body veins can lead to Deep Vein Thrombosis (DVT). Several such instances have led to lawsuits across the U.S. (Matthews & Associates Law Firm has filed several such lawsuits. Contact the firm if you or someone you love has been injured by Yaz, Yasmin or Ocella.)
See the British Medical Journal research which discourages use of these products:
The Food & Drug Administration (FDA) has warned Bayer Healthcare Pharmaceuticals, the maker of Yaz and Yasmin, of its potential legal liability in marketing these drugs. The FDA issued a warning to Bayer in Oct. 2008 regarding the company’s Yaz and Yasmin television advertisements. FDA regulators warned of the company’s potentially misleading and dangerous language in describing Yaz and Yasmin uses and risks, including:
* understating health risks
* claiming these drugs could mollify symptoms associated with PMS when they were NOT approved for this purpose
* claiming these drugs could help reduce moderate acne when they were NOT approved for this purpose
Bayer agreed to terms being pursued by 27 different state Attorneys General as well as the FDA to air new commercials that removed unapproved medical claims, corrected misinformation and added more direct language regarding health risks.
The progestin compound unique to these birth control pills, drospirenone, is considered a diuretic. Diuretics can cause dehydration and dangerous elevations of blood potassium.
Concentration of potassium levels in the blood stream can affect cardiac rhythm, which can create blood flow problems that have been attributed to potentially fatal symptoms such as:
pulmonary embolism (blood clots in lungs)
deep vein thrombosis (DVT)
intracardiac thrombosis (blood clots in the heart)
The FDA has received more than fifty death reports related to the use of Yaz/Yasmin/Ocella, some occurring among young women who are ordinarily at low risk of such conditions.
Yaz and Yasmin were the two biggest selling oral contraceptives in the world in the first quarter of 2009, accounting for more than $1.8 billion in revenues for Bayer Pharmaceutical.
Matthews & Associates Law Firm (offices in Houston and New York) has filed more than two dozen Yaz, Yazmin and Ocella cases across the country.